Home/Filings/4/0001209191-23-059636
4//SEC Filing

Shendelman Shoshana 4

Accession 0001209191-23-059636

CIK 0001697532other

Filed

Dec 21, 7:00 PM ET

Accepted

Dec 22, 8:01 PM ET

Size

11.8 KB

Accession

0001209191-23-059636

Insider Transaction Report

Form 4
Period: 2023-12-21
Shendelman Shoshana
DirectorPresident and CEO10% Owner
Transactions
  • Award

    Common Stock

    2023-12-21+1,100,0003,696,387 total
  • Award

    Common Stock

    2023-12-21+440,0004,136,387 total
Holdings
  • Common Stock

    (indirect: See footnote)
    1,750,000
  • Common Stock

    (indirect: See footnote)
    290,280
  • Common Stock

    (indirect: See footnote)
    88,397
  • Common Stock

    (indirect: See footnote)
    1,492,094
  • Common Stock

    (indirect: See footnote)
    709,720
Footnotes (7)
  • [F1]Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the compensatory Restricted Stock Units shall vest on December 21, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory Restricted Stock Units shall vest each month thereafter, subject to the reporting person continuing to provide services through each such date.
  • [F2]Consists of compensatory Restricted Stock Units granted under the Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. These compensatory Restricted Stock Units are subject to both performance and time-based vesting requirements, subject to the reporting person continuing to provide services through each such date. The performance-based vesting requirements shall be satisfied upon the issuer's stock price trading at or above $6.00 per share for twenty consecutive trading days during a four-year performance period. The time-based vesting requirements shall be satisfied on the same schedule as applies to the time-based awards referenced in footnote (1) above.
  • [F3]Through a grantor retained annuity trust.
  • [F4]Through a family trust controlled by the reporting person's spouse.
  • [F5]Through the reporting person's spouse.
  • [F6]Through a family trust controlled by the reporting person.
  • [F7]Through Clearpoint Strategy Group LLC of which the reporting person is the sole owner.

Issuer

Applied Therapeutics Inc.

CIK 0001697532

Entity typeother

Related Parties

1
  • filerCIK 0001775490

Filing Metadata

Form type
4
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 8:01 PM ET
Size
11.8 KB